The antibody drug conjugates industry in North America is witnessing rapid expansion due to the increasing burden of cancer and the growing demand for targeted therapeutics. Antibody drug conjugates, commonly referred to as ADCs, combine monoclonal antibodies with cytotoxic drugs to deliver precise treatment while minimizing damage to healthy tissues. This therapeutic approach has become...